Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | CFTR | P13569 | 8/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 2/20 | 0.37 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31752450 | 0.85 | NPSR1 (0.44) | NPSR1CFTRKDM4EALDH1A1HSD17B10 | |
| SCHEMBL30475032 | 0.85 | NPSR1 (0.44) | NPSR1CFTRKDM4EALDH1A1HSD17B10 | |
| SCHEMBL18405257 | 0.85 | NPSR1 (0.44) | NPSR1CFTRKDM4EALDH1A1HSD17B10 | |
| SCHEMBL25305744 | 0.85 | NPSR1 (0.44) | NPSR1CFTRKDM4EALDH1A1HSD17B10 | |
| SCHEMBL28495356 | 0.83 | NPSR1 (0.42) | NPSR1CFTRKDM4EALDH1A1HSD17B10 | |
| SCHEMBL30218091 | 0.83 | NPSR1 (0.42) | NPSR1CFTRKDM4EALDH1A1HSD17B10 | |
| SCHEMBL4772527 | 0.83 | NQO2 (0.45) | NPSR1CFTRKDM4EALDH1A1HSD17B10 | |
| SCHEMBL25096003 | 0.83 | NPSR1 (0.42) | NPSR1CFTRKDM4EALDH1A1HSD17B10 | |
| SCHEMBL318846 | 0.83 | CFTR (0.44) | NPSR1CFTRKDM4EALDH1A1HSD17B10 | |
| SCHEMBL25263446 | 0.80 | CFTR (0.48) | NPSR1CFTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122218-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2025-04-17 | — | — | US | disclosed |
| EP-4476230-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2024-12-18 | — | — | EP | disclosed |
| WO-2023154291-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023154291-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122218-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | NPSR1 3829/4885CFTR 1/4885KDM4E 4100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.